Catalog No.: PC-27660Not For Human Use, Lab Use Only.
Ecubectedin is an ecteinascidin synthetic analogue and selective inhibitor of transcription, reducing cell proliferation and migration, as well as inducing S-phase cell cycle arrest and DNA damage in malignant pleural mesothelioma cells.
Ecubectedin is an ecteinascidin synthetic analogue and selective inhibitor of transcription, reducing cell proliferation and migration, as well as inducing S-phase cell cycle arrest and DNA damage in malignant pleural mesothelioma cells.
Ecubectedin inhibits cell viability in a panel of twelve 2D-cultures of patient-derived MPM, independent of histotype or BAP1 status, with mean IC50 of 0.06 nM.
Ecubectedin strongly impairs invasion, migration and cell cycle of MPM cells, down-regulates DNA damage sensors (ABL1, BRCA1 and TP53) and up-regulated repair machinery genes (ATR, ATM, CHEK1, CHEK2, PRKDC and RAD51), activates the cGAS/STING pathway.
Ecubectedin induces immunogenic cell death and immune killing by CD8+T-lymphocytes, reshaping the MPM immune-environment.
Ecubectedin increased the efficacy of atezolizumab in immune-PDX models of MPM.
